Rationale for Early Diagnosis of Mild Cognitive Impairment (MCI) supported by Emerging Digital Technologies
Year: 2020
Type: review
Abstract: Disease-modifying pharmacotherapies for Alzheimer's Disease (AD) are currently in late-stage clinical development; once approved, new healthcare infrastructures and services, including primary healthcare, will be necessary to accommodate a huge demand for early and large-scale detection of AD. The increasing global accessibility of digital consumer electronics has opened up new prospects for early diagnosis and management of mild cognitive impairment (MCI) with particular regard to AD. This new wave of innovation has spurred research in both academia and industry, aimed at developing and validating a new "digital generation" of tools for the assessment of the cognitive performance. In light of this paradigm shift, an international working group (the Global Advisory Group on Future MCI Care Pathways) convened to elaborate on how digital tools may be optimally integrated in screening-diagnostic pathways of AD The working group developed consensus perspectives on new algorithms for large-scale screening, detection, and diagnosis of individuals with MCI within primary medical care delivery. In addition, the expert panel addressed operational aspects concerning the implementation of unsupervised at-home testing of cognitive performance. The ultimate intent of the working group's consensus perspectives is to provide guidance to developers of cognitive tests and tools to facilitate the transition toward globally accessible cognitive screening aimed at the early detection, diagnosis, and management of MCI due to AD.
Institutions: Cleveland Clinic, Lou Ruvo Brain Institute, Instituto de Salud Carlos III, Universitat Internacional de Catalunya, Biomedical Research Networking Center on Neurodegenerative Diseases, Fundació ACE, University of Washington, Duke University, Duke Medical Center, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital, The University of Tokyo, University of Rochester Medicine, University of Rochester, University of California, San Francisco, Université de Toulouse, Eisai (United States)
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,990
Funders: U.S. Department of Defense, Eli Lilly and Company, Pfizer, AstraZeneca, Biogen, Alnylam Pharmaceuticals, ACADIA Pharmaceuticals, Quest Diagnostics, European Commission, Daiichi-Sankyo, Eisai, Servier, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Grifols, National Institutes of Health, Genentech, Chugai Pharmaceutical, Instituto de Salud Carlos III, National Institute on Aging, Office of Naval Research, National Institute of Mental Health
OpenAlex ID: W3014561849
